Skip to content

CareDx CDNA Contingent consideration

Contingent consideration at other companies

Braze, Inc. logo
Braze, Inc.BRZE
$0
RingCentral logo
RingCentralRNG
$1.9M
Werner Enterprises logo
Werner EnterprisesWERN
$30M
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$15.79M-10.1%
Provident Financial Services logo
Provident Financial ServicesPFS
$560K+28.4%
StepStone Group Inc. logo
StepStone Group Inc.STEP
$1.45M

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B-9.6%
Enterprise value$1.35B-9.7%
P/S3.4×-1.1×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept cdna:CommonStockSharesIssuedForContingentConsideration.

The official record: CareDx’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's contingent consideration?
CareDx (CDNA) reported contingent consideration of $0 in Q4 2025.
What is the long-term trend for CareDx's contingent consideration?
Over 4 years (2021 to 2025), CareDx's contingent consideration has grown at a -100.0% compound annual growth rate (CAGR), from $5.34M to $0.
What does contingent consideration mean?
Represents the value of common stock issued to satisfy earn-out or contingent payment obligations resulting from past business acquisitions. This metric is critical for assessing the long-term cost of inorganic growth strategies and the potential dilution impact on existing shareholders.